Another quarter goes in the books and Medtronic (MDT) investors are still waiting to see some real signs of life when it comes to re-igniting top line growth. Although nobody questions Medtronic's ability to maintain leadership positions in many large med-tech markets, there are ample questions as to whether the company can translate this leadership into growth. Current conditions being what they are, investors have to put a lot more of their hopes on future product and market developments to make this stock look appealing today.
A Disappointing Fiscal Third Quarter
To be fair, Medtronic's "disappointment" relative to expectations was not that bad in an absolute sense. More problematic, though, is how it undermines the idea that 2012 conditions will get significantly better in some core markets.
Read more here:
Medtronic's Growth Problems Still Front And Center
No comments:
Post a Comment